NYHETER

Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study - Only Marketed Oral MS Therapy with Positive Data in Patients who Experienced Initial Attack Suggestive of MS - Cambridge, Mass. – April 25, 2013 – Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY) announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS). Mere > Effect of Genzyme’s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies Cambridge, Mass. – March 21, 2013 – Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today interim results from the first year of the extension study of LEMTRADA™ (alemtuzumab), being developed for the treatment for multiple sclerosis (MS). Mere > Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs Cambridge, Mass. – March 13, 2013 – Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today that data from its AUBAGIO® (teriflunomide) and LEMTRADATM (alemtuzumab) multiple sclerosis clinical development programs will be presented during the 65th American Academy of Neurology (AAN) Annual Meeting to be held in San Diego, Calif., March 16-23. Mere > Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS) CAMBRIDGE, Mass. – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that it has received a Company Award from EURORDIS, the largest European patient organization in the field of rare diseases. The EURORDIS Company Award recognizes the outstanding accomplishments of companies dedicated to rare diseases. Genzyme was honored for pioneering the development and delivery of therapies for rare diseases, its longstanding support of patient organizations, including EURORDIS, as well as initiatives to increase patient access to Genzyme... Mere >